Q3 Earnings Estimate for Fate Therapeutics Issued By Wedbush

Key Points

• Wedbush raised its Q3 2025 earnings estimate for Fate Therapeutics from ($0.38) to ($0.30) per share, reflecting a more optimistic outlook for the biopharmaceutical company.
• Fate Therapeutics' stock is currently rated as "Hold" by analysts, with an average price target of $3.58, while several firms have recently downgraded their price objectives significantly.
• The company reported a loss of ($0.29) EPS in its latest quarter, surpassing the consensus estimate of ($0.35) EPS, with revenues of $1.91 million compared to expectations of $1.16 million.

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Stock analysts at Wedbush boosted their Q3 2025 earnings per share estimates for Fate Therapeutics in a note issued to investors on Wednesday, August 13th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.30) per share for the quarter, up from their previous estimate of ($0.38). The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share. Wedbush also issued estimates for Fate Therapeutics' Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.40) EPS, FY2028 earnings at ($0.61) EPS and FY2029 earnings at ($0.59) EPS.

A number of other analysts have also commented on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, June 12th. Wall Street Zen downgraded Fate Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 10th. Barclays reduced their target price on Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Robert W. Baird reduced their target price on Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company reduced their target price on Fate Therapeutics from $4.00 to $2.50 and set an "equal weight" rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Fate Therapeutics currently has an average rating of "Hold" and a consensus target price of $3.58.

Fate Therapeutics Stock Up 1.9%

Shares of FATE traded up $0.02 during trading hours on Friday, reaching $1.09. 1,665,729 shares of the company traded hands, compared to its average volume of 1,594,353. The stock has a market capitalization of $125.71 million, a PE ratio of -0.75 and a beta of 2.24. Fate Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $4.20. The stock has a fifty day simple moving average of $1.16 and a 200 day simple moving average of $1.14.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The business had revenue of $1.91 million for the quarter, compared to analyst estimates of $1.16 million. Fate Therapeutics had a negative return on equity of 50.95% and a negative net margin of 2,025.05%.

Hedge Funds Weigh In On Fate Therapeutics

Large investors have recently modified their holdings of the company. Squarepoint Ops LLC raised its holdings in shares of Fate Therapeutics by 154.2% in the 4th quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 20,805 shares during the period. Hsbc Holdings PLC raised its holdings in shares of Fate Therapeutics by 22.0% in the 4th quarter. Hsbc Holdings PLC now owns 109,422 shares of the biopharmaceutical company's stock worth $179,000 after purchasing an additional 19,706 shares during the period. Millennium Management LLC raised its holdings in shares of Fate Therapeutics by 28.9% in the 4th quarter. Millennium Management LLC now owns 413,192 shares of the biopharmaceutical company's stock worth $682,000 after purchasing an additional 92,576 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Fate Therapeutics by 10.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,898,377 shares of the biopharmaceutical company's stock worth $4,782,000 after purchasing an additional 279,360 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in shares of Fate Therapeutics by 56.3% in the 4th quarter. Wells Fargo & Company MN now owns 92,395 shares of the biopharmaceutical company's stock worth $152,000 after purchasing an additional 33,284 shares during the period. 97.54% of the stock is currently owned by hedge funds and other institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.